Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis

Abstract

Current therapies in oncology that offer a longer and better quality of life are leading to more cases where cancer and chronic diseases coexist. Enzalutamide, a second-generation anti-androgen agent, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There is no series with many patients on the use of enzalutamide in patients with end-stage renal disease (ESRD). We present a patient diagnosed with mCRPC who was followed up with enzalutamide treatment for about 5 years after progression with docetaxel and who was on hemodialysis 3 days a week.

Keywords

• Enzalutamide
• prostate cancer
• renal failure

Hemodiyalize Giren Prostat Kanserli Hastada Enzalutamid ile Uzun Süreli Yanıt

Abstract

Onkolojide daha uzun ve kaliteli bir yaşam sunan güncel tedaviler, kanser ve kronik hastalıkların bir arada görüldüğü vakaların artmasına neden olmaktadır. İkinci nesil bir anti-androjen ajan olan enzalutamid, metastatik kastrasyona dirençli prostat kanseri (mCRPC) tedavisi için 2012 yılında ABD Gıda ve İlaç Dairesi (FDA) tarafından onaylanmıştır. Son dönem böbrek hastalığı (SDBH) olan hastalarda enzalutamid kullanımına ilişkin çok sayıda hasta içeren bir seri bulunmamaktadır. Bu çalışmada, dosetaksel ile progresyon sonrası yaklaşık 5 yıldır enzalutamid tedavisi ile takip edilen ve haftada 3 gün hemodiyalize giren mCRPC tanılı bir hastayı sunuyoruz.

Keywords

• Enzalutamid
• prostat kanseri
• böbrek yetmezliği

References

1. 1. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol [Internet]. 2021 Feb 1 [cited 2022 Aug 19];79(2):243–62. Available from: https://pubmed.ncbi.nlm.nih.gov/33172724/
2. 2. Seok Han K, Joon Hong S. Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer. Yonsei Med J [Internet]. 2015;56:368. Available from: http://dx.doi.org/10.3349/ymj.2015.56.2.368
3. 3. Takimoto T, Nakabori T, Osa A, Morita S, Terada H, Oseto S, et al. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.
4. 4. Loriot Y, Fizazi K, De Bono JS, Forer D, Hirmand M, Scher HI. Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial Running title: Enzalutamide and visceral mets in AFFIRM.
5. 5. Schwartz GG. Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases. Cancer Epidemiol Biomarkers Prev [Internet]. 2008 Mar 1 [cited 2022 Sep 13];17(3):478–83. Available from: https://aacrjournals.org/cebp/article/17/3/478/11031/Prostate-Cancer-Serum-Parathyroid-Hormone-and-the
6. 6. Tarhan F, Orçun A, Küçükercan I, Çamursoy N, Kuyumcuoǧlu U. Effect of hemodialysis on serum complexed prostate-specific antigen levels. Scand J Urol Nephrol [Internet]. 2007 [cited 2022 Sep 11];41(5):382–6. Available from: https://pubmed.ncbi.nlm.nih.gov/17853041/
7. 7. Singh Z, Holt SK, Gore JL, Nyame YA, Wright JL, Schade GR. Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation. Eur Urol Open Sci. 2022 May 1;39:79–82.
8. 8. van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, et al. Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis. Clin Genitourin Cancer. 2019;17(2):e383–6.

9. 9. Simões J, Augusto I, Meireles S, Vendeira L, Silva C. Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis. 2018; Available from: http://dx.doi.org/10.4322/acr.2018.011
10. 10. Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, et al. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. Eur Urol Oncol. 2019 Nov 1;2(6):677–84.